Risk Stratification for Primary Prevention of Sudden Cardiac Death in Hypertrophic Cardiomyopathy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. OPTEM-oHCM: OPtimal Targeted Polymer-based EMbolization for Obstructive Hypertrophic CardioMyopathy.JACC. Case reports · 2025
   Article
2. Exploring the Current Status of Risk Stratification in Hypertrophic Cardiomyopathy: From Risk Models to Promising Techniques.Journal of cardiovascular development and disease · 2025
   Review
3. Septal Artery Embolization with Onyx® In Hypertrophic Cardiomyopathy: Report of Two Cases.Arquivos brasileiros de cardiologia · 2025
   Article

Corrections and comments

• Comment on
  Discrepancy between International Guidelines on the Criteria for Primary Prevention of Sudden Cardiac Death in Hypertrophic Cardiomyopathy.2020

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as